Status:
COMPLETED
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherap...
Eligibility Criteria
Inclusion
- A condition of general good health
- BMI 19 to 29
Exclusion
- Currently enrolled in another clinical study
- Females who are pregnant or breast-feeding
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00826358
Start Date
November 1 2008
Last Update
September 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 13441
Orlando, Florida, United States, 32809